EPO and Parkinson disease: When systemic (intravenous) administration of EPO and intrastriatal injected EPO were compared in a PD animal model, the blood-brain barrier appeared to limit the passage of EPO into the brain as only low levels of EPO crossed despite a high intravenous dose [18, 31, 32].